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Introduction 26 
 27 
There are approximately 92 million new chlamydial infections of the genital tract in 28 
humans diagnosed each year [1], costing health care systems billions of dollars in 29 
treatment not only of acute infections, but also of associated inflammatory sequelae, 30 
such as pelvic inflammatory disease (PID) and ectopic pregnancy [2]. These 31 
numbers are increasing at a steady rate [3] and, due to the asymptomatic nature of 32 
infections, the incidence may be underestimated and the costs of treatment therefore 33 
higher. Over the previous few decades there has been a large amount of research 34 
into the development of an efficacious vaccine against genital tract chlamydial 35 
infections [4]. The majority of this research has focused on females, due to the high 36 
rate of development of associated diseases, including PID, which can lead to ectopic 37 
pregnancy and infertility [5]. In light of the increasing infection rates that have 38 
occurred despite the availability of antibiotics, and the asymptomatic nature of 39 
chlamydial infections, it is imperative that an efficacious vaccine that protects against 40 
infection and associated pathology be developed. 41 
 42 
It is widely accepted that a protective chlamydial vaccine needs to induce a strong 43 
Th1 immune response, causing an increase in IFN- secreting CD4+ T cell infiltration 44 
to the infection site [6], and induce the secretion of neutralizing antibodies at the 45 
mucosal surface [7]. However, there is the chance that an overstimulation of the 46 
immune system with vaccination could lead to the development of enhanced 47 
pathology. For example, the increased production of TNF-α has been shown to aid in 48 
clearance of a genital infection [8, 9], but it is also a pro-inflammatory cytokine that 49 
can stimulate the production of other cytokines. This enhancement of cytokine 50 
 
 
production can contribute to immune-mediated damage to the reproductive tract [10-51 
12]. Therefore, any successful vaccine must contain both antigens and adjuvants 52 
that induce a balance between providing protective immunity and not contributing to 53 
immune-associated disease pathogenesis.  54 
 55 
Major issues relating to chlamydial vaccine development, which have not been 56 
examined to date, are the effect of vaccination on an individual that has previously 57 
been exposed to an infection, and how re-exposure of the individual to a genital 58 
infection after vaccination may affect the final outcomes. Very early trachoma 59 
vaccine trials, that used whole killed Chlamydia as the vaccine, examined the effects 60 
of immunization on blind individuals who had had a previous trachoma infection [13, 61 
14]. These individuals were then given a second chlamydial ocular infection, and it 62 
was found that those that were immunized developed more severe pathology, 63 
compared to those that were mock immunized. Very similar studies have been 64 
performed in monkeys revealing the same phenomenon [15, 16]. It was suggested 65 
that the enhancement of pathology in the monkeys was due to the high homology 66 
between chlamydial heat shock protein – 60 (HSP-60) and self HSP-60, contributing 67 
to autoimmunity [16]. Due to the advancement of molecular technologies, individual 68 
antigens can now be identified and screened, thereby avoiding possible molecular 69 
mimicry. Because the rates of genital tract chlamydial infections are steadily rising, 70 
and therefore the rates of previous exposure, research into this aspect of vaccine 71 
development is essential. 72 
 73 
The effect of vaccination of individuals who have an active chlamydial genital tract 74 
infection is another important aspect of chlamydial vaccine studies that has not yet 75 
 
 
been examined in any way. Due to the asymptomatic nature of chlamydial genital 76 
tract infections, with approximately 70% of infected women showing no symptoms 77 
[17], it is imperative that this aspect, of vaccination during infection be examined. 78 
While it is not expected, it is possible that vaccination during an acute infection may 79 
affect the course and degree of infection in the genital tract. It is unknown whether 80 
vaccination will boost the already active immune system and enhance clearance, or 81 
if any enhancement of the immune response will further exacerbate pathology 82 
development. Further stimulation of immune cells through immunization may 83 
increase pro-inflammatory cytokine production and further increase cellular infiltrate 84 
into the genital tract, contributing to the development of long term sequelae in 85 
women. 86 
 87 
The current study utilized the already developed vaccine candidates, the major outer 88 
membrane protein (MOMP) [18, 19] and ribonucleotide reductase small chain protein 89 
sub-unit B (NrdB) [20] of C. muridarum, administered intranasally, to examine the 90 
effects of timing of vaccination in a murine model of chlamydial genital tract infection. 91 
Firstly, we aimed to examine whether immunization during an acute genital infection, 92 
or after clearance of a genital infection, enhanced immune responses above that 93 
induced by an infection alone. Secondly, we aimed to determine if the timing of 94 
vaccination enhanced or reduced the development of pathology in the reproductive 95 
tract of mice immunized with our vaccines. Finally, we aimed to determine whether 96 
immunization during a genital infection had any therapeutic effect, and also whether 97 
it provided extra protection against a second genital tract chlamydial infection. 98 
 99 
 100 
 
 
Materials and Methods 101 
Chlamydia strain 102 
Chlamydia muridarum (Weiss; ATCC VR-123, Virginia, USA), formerly the mouse 103 
pneumonitis biovar of C. trachomatis (MoPn), was grown by inoculation of McCoy 104 
cell (ATCC CRL-1696, Virginia, USA) monolayers in Dulbecco’s minimal essential 105 
medium supplemented with 5% fetal calf serum, 2mM L-glutamine, 100µg/mL 106 
Streptomycin sulfate, 2µg/mL Gentamycin and 20mM HEPES. Elementary bodies 107 
were purified using a discontinuous Renografin gradient as previously described 108 
[21]. 109 
 110 
Protein production/purification 111 
Major outer membrane protein (MOMP) 112 
The transformed Escherichia coli (DH5{pMMM3}) expressing the pMAL-c2 vector 113 
encoding recombinant MBP-MOMP fusion protein was a generous gift from Harlan 114 
Caldwell (Rocky Mountain Labs, Hamilton, MT, USA). MBP-MOMP was produced as 115 
previously described [18].  116 
 117 
Ribonucleotide reductase small chain protein sub-unit B (NrdB) 118 
Transformed E. coli (BL21 DE3) expressing the pCOLD vector (TaKaRa, Shiga, 119 
Japan) encoding recombinant His-tagged NrdB was produced and purified. Clonal E. 120 
coli colonies were grown overnight at 37ºC in 5mL LB broth containing ampicillin. 121 
This was transferred to 500ml of LB broth containing ampicillin and cultured at 37ºC 122 
and 225rpm until an OD measurement of 0.4-0.5 was obtained at 600nm. Cultures 123 
were chilled on ice for 30mins. Protein production was induced by the addition of 124 
0.5mM IPTG (Sigma-Aldrich, North Ryde, NSW, Australia), final concentration, and 125 
 
 
cultures were incubated overnight at 15°C and 225rpm. Cells were collected via 126 
centrifugation at 10,000 x g for 10 minutes at 4°C. Pellets were resuspended in 127 
50mL PBS, 0.15g Lysozyme (Sigma-Aldrich) was added and cells incubated at 37°C 128 
for 1 hour. Bacterial protease cocktail inhibitor (Sigma-Aldrich) was added according 129 
to the manufacturer’s instructions and 1mM PMSF (Sigma-Aldrich), final 130 
concentration, was added. Cells were aliquoted to 10mL and sonicated in 15 second 131 
cycles a total of 8 times, after which time they were spun at 4,000 x g, 4°C for 10 132 
minutes. Supernatants were then spun at 10,000 x g for 10 minutes at 4°C, and 133 
supernatants frozen at -20°C until purification. 134 
 135 
Purification of NrdB was performed using the batch/gravity-flow column purification 136 
as described by the manufacturers (Talon Resin, BD Biosciences, North Ryde, 137 
NSW, Australia). Eluted protein fractions were analyzed via SDS-page. Fractions 138 
containing protein were dialyzed using cellulose dialysis membrane with an 8kDa 139 
cut-off (Sigma-Aldrich) in PBS, and then concentrated using Amplicon concentrators 140 
(Millipore, North Ryde, NSW, Australia) with a cut-off of 10kDa. 141 
 142 
Mice 143 
Female BALB/c mice, 6-8 weeks of age, were obtained from The Animal Resource 144 
Centre, Perth (Australia), and housed in an accredited laboratory animal care facility 145 
under specific-pathogen free conditions. Animals received food and water ad libitum. 146 
All procedures were approved by the Queensland University of Technology Animal 147 
Research Ethics Committees. Five animals were used in each group and each 148 
experiment was repeated twice. 149 
 150 
 
 
Infection and monitoring 151 
Mice were given 2.5mg of medroxyprogesterone acetate (Depo-Provera, Pfizer, 152 
West Ryde, NSW, Australia) subcutaneously, seven days prior to infection. The mice 153 
were anaesthetised intraperitoneally using ketamine (90 mg/kg; Parnell Laboratory, 154 
Alexandria, NSW, Australia) and xylazine hydrochloride (10 mg/kg; Bayer, Pymble, 155 
NSW, Australia) and infected intra-vaginally with 20µl of sucrose-phosphate-156 
glutamate (SPG) containing 5 x 104 inclusion forming units (ifu) of C. muridarum. 157 
 158 
Immunization 159 
Animals were lightly anaesthetized with 4% isoflurane. Appropriate, equal volumes of 160 
immunization solution were placed on each nare for animals to inhale. Immunization 161 
solutions consisted of 5μg cholera toxin (CT; List Biological Laboratories, Campbell, 162 
CA, USA), 10μg CpG-ODN (sequence: 5’-TCCATGACGTTCCTGACGTT -3’; Sigma-163 
Aldrich), and 50μg of either MOMP alone or 50μg of MOMP and 50μg NrdB in 164 
combination. All immunization solutions were made up to equal volumes using sterile 165 
PBS. Mice were immunized naïve, during an acute genital chlamydial infection, or 166 
after clearance of a genital chlamydial infection in accordance with figure 1. 167 
 168 
Detection of C. muridarum infection 169 
Infection was monitored by collecting cervico-vaginal swabs (Copan, Murrieta, CA, 170 
USA) every three days post infection. Swabs were placed in tubes containing 500l 171 
SPG and glass beads and were stored at -80°C. To monitor infection levels, swabs 172 
were cultured as described elsewhere [22]. The chlamydial inclusions were 173 
visualised by staining with rabbit anti-C. trachomatis antibody (Pierce/Progen, 174 
 
 
Richlands, Australia) and Immunopure ABC/DAB Staining Kit (Pierce/Progen, 175 
Richlands, Australia), as described elsewhere [18]. 176 
 177 
Sample collection 178 
At the termination of the experiments (Fig. 1), animals were euthanized using a lethal 179 
injection of sodium pentobarbitone. Blood was collected via cardiac puncture, 180 
centrifuged at 12,000 x g and serum was collected. Vaginal lavage was collected by 181 
flushing the vaginal vault with 40µL of sterile PBS and uterine lavage was collected 182 
by removing the horns from the animal and flushing with 100µL sterile PBS. All 183 
samples were stored at -20°C until testing. 184 
 185 
T cell proliferation and cytokine assessment 186 
Spleens were removed from animals and processed as described elsewhere [18]. 187 
Cells were plated into 96 well tissue culture plates at 5 x 105 cells/well. Stimulants 188 
were added to wells (2 µg/well MOMP, 2 µg/well NrdB or media) and cells were 189 
incubated for 4 days. Supernatants were collects and centrifuged at 500 x g for 10 190 
mins to removed debris. Supernatants were assayed for IL-4, IL-10, IFN-γ and IL-191 
12p(70) using Bio-Plex bead array system (Bio-rad, North Ryde, NSW, Australia) 192 
according to manufacturer’s instructions. 193 
 194 
ELISA’s 195 
Ninety six well plates (Interpath, Heidelberg West, VIC, Australia) were coated with 196 
2g/well of protein (MBP-MOMP or His-NrdB) and incubated at 4°C overnight. 197 
ELISA’s were performed as described previously [18]. The antibodies used were 198 
anti-mouse IgG or anti-mouse IgA  (Southern Biotechnology Associates, AL, USA) at 199 
 
 
a 1/1000 dilution, and horseradish peroxidase (HRP)-conjugated streptavidin 200 
(Amersham Life Science, NJ, USA) at a 1/1000 dilution. The end point titre (EPT) 201 
was determined by the dilution at which the absorbance became equivalent to that of 202 
the EPT threshold. The EPT threshold was calculated as the average absorbance of 203 
the no sample control + 2 standard deviations. 204 
 205 
Gross pathology 206 
After euthanasia, the reproductive tracts were examined in situ for macroscopic 207 
changes. The degree of hydrosalpinx development was recorded and grouped as 208 
described previously [22]. Briefly, swelling of the oviduct between 2-3mm was scored 209 
1, 3-5mm was scored 2 and >5mm was scored 3. 210 
 211 
Histological assessment 212 
Excised genital tract tissues were removed at euthanasia, fixed in 10% formaldehyde 213 
and embedded in paraffin wax. Five µm sections were cut, dewaxed and rehydrated 214 
through graded ethanol solutions to PBS. Haematoxylin and eosin staining was 215 
performed. Ten random fields ( 1000 magnification) of each tissue were counted 216 
ensuring to include both epithelium and sub-mucosa, with the observer blinded to the 217 
group being examined. 218 
 219 
Statistics 220 
All data presented are mean ± standard error of mean (SEM). All statistics were 221 
performed using GraphPad Prism version 5.00 (GraphPad Software, La Jolla, CA, 222 
USA). Significant differences for the ELISA, hydrosalpinx and inflammatory cell 223 
infiltrate was determined using two-way ANOVA, with Bonferroni’s post test and 224 
 
 
significance was set at p<0.05. Unpaired students t-tests were used to calculate 225 
significant differences in clearance, with significance set at p<0.05. 226 
 227 
 228 
 229 
 230 
 231 
 232 
 233 
 234 
 235 
 236 
 237 
 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 
 
Results 250 
 251 
The effects of the timing of vaccination on antibody production, hydrosalpinx 252 
formation and inflammatory cell infiltration were examined. In the case of those 253 
animals immunized during an acute infection, the therapeutic effect of the 254 
vaccination was investigated, as was the effect on a secondary infection. Animals 255 
were immunized intranasally (IN) with the adjuvants cholera toxin (CT) and CpG-256 
ODN, and the antigens the major outer membrane protein (MOMP) or MOMP and 257 
ribonucleotide reductase small chain protein subunit B (NrdB) in combination (Fig. 258 
1). These vaccine formulations have previously proven to induce T cell and antibody 259 
responses, and provide protection against genital infection [18-20].  260 
 261 
The timing of vaccination alters the systemic but not local anti-chlamydial 262 
antibody production 263 
Examination of MOMP and NrdB–specific systemic IgG in response to immunization 264 
of naïve mice and those animals immunized at various stages of a chlamydial 265 
infection revealed that the timing of vaccination had an effect on systemic antibody 266 
production. The infection alone groups served as time point controls, as they were 267 
infected, only once, at the same time as those that received any form of 268 
immunization, allowing any enhanced antibody production as a result of vaccination 269 
to be determined. The live immunization controls (LIC) were infected twice, with 270 
infections 10 weeks apart, and served as the positive control.  271 
 272 
In terms of MOMP-specific serum IgG production (Fig. 2A) the greatest effects were 273 
seen in those animals that were immunized during infection. While IN immunization 274 
 
 
of naïve mice with CT/CpG/MOMP produced a significant (p<0.001) amount of 275 
serum IgG compared to the LIC group (Fig. 2A), those immunized during infection 276 
with the same formulation produced approximately 3 fold more MOMP-specific IgG 277 
(p<0.001). Examination of systemic NrdB-specific IgG production (Fig. 2B) revealed 278 
that those mice receiving CT/CpG/MOMP/NrdB had similar levels of NrdB and 279 
MOMP-specific antibodies present. Immunization with the dual antigen formulation, 280 
during an infection, caused a significant increase (p<0.001) in NrdB-specific antibody 281 
production than when administered to naïve mice (Fig. 2B). NrdB antibodies were 282 
not detected in the animals that were infected only, or in the animals in the LIC 283 
group. Interestingly, there was no enhancement of MOMP or NrdB-specific IgG 284 
produced when animals were re-challenged with C. muridarum after infection and 285 
immunization (Fig 2A and 2B). 286 
 287 
While immunization of mice with the various vaccine compositions produced MOMP–288 
specific IgA at the vaginal mucosa (Fig. 3A), the timing of vaccination did not affect 289 
the levels of MOMP-specific IgA, as none were significantly greater than the infection 290 
only animals. Specifically, those animals immunized with CT/CpG/MOMP/NrdB after 291 
clearance of infection produced 2-fold less MOMP-specific IgA than those 292 
immunized naïve (p<0.01) or during an infection (p<0.05; Fig. 3A). Production of 293 
NrdB-specific IgA at the vaginal mucosa (Fig. 3B) was approximately 10-fold less 294 
compared to the levels of MOMP-specific IgA detected. There was a trend found, 295 
with those immunized with CT/CpG/MOMP/NrdB, during an infection, producing 296 
greater amounts of NrdB specific antibodies than those immunized naïve with the 297 
same formulation. 298 
 299 
 
 
Examination of MOMP-specific IgA in uterine lavage (Fig. 4A) revealed that, while 300 
IgA production occurred, the timing of immunization did not significantly affect the 301 
levels of antibody being produced. Production of NrdB-specific IgA in the uterine 302 
horn (Fig. 4B) was most evident in those mice immunized after clearance of 303 
infection, with those immunized with CT/CpG/MOMP/NrdB producing the greatest 304 
amount; however this was not significantly greater than that detected in animals that 305 
were only infected. 306 
 307 
Immunization leads to a balanced Th1 and Th2 T cell response. 308 
The production of IL-4 and IL-10 were measured to determine the Th2 response in 309 
animals and the production of IL-12p(70) and IFN-γ to determine the Th1 response. 310 
In those animals that were immunized naïve (without infection) there were very low 311 
levels of all cytokines produced in response to MOMP or NrdB stimulation (Fig. 5A). 312 
In those animals receiving vaccination during an infection there was an overall 313 
balanced Th1 verses Th2 response with production of both IL-10 and IFN-γ in the 314 
CT/CpG/MOMP/NrdB group (Fig. 5B). The CT/CpG/MOMP group produced minimal 315 
cytokines in response to stimulation. In the mice immunized after clearance of an 316 
infection mice receiving either single or dual antigen vaccines produced IL-4, IL-10, 317 
IFN-γ and low levels of IL-12p(70) indicating both a Th1 and Th2 T cell immune 318 
response (Fig. 5C). Overall the addition of MOMP was the strongest stimulant, 319 
causing the majority of cytokine production. 320 
 321 
Immunization has no therapeutic effect and does not provide enhanced 322 
protection against re-exposure 323 
 
 
Mice were immunized either with a single or dual antigen vaccine naïve or during an 324 
acute C. muridarum vaginal infection. Comparison of those immunized naïve (Fig. 325 
5A) and during an infection (Fig. 5B) with a single antigen vaccine demonstrates that 326 
there is no difference in the levels or course of infection. For those mice immunized 327 
with the dual vaccine formulation it can be seen that although those immunized 328 
naïve still have a very low level of infection at day 21 post infection (only one positive 329 
animal), this is not significantly different from those immunized during infection who 330 
clear infection at day 18. It can be seen in figure 6B that there were no significant 331 
differences detected between the mice that received only the adjuvants and those 332 
that received the complete vaccine formulations. There were also no significant 333 
differences observed in the rate of clearance of Chlamydia from the lower genital 334 
tract of mice either immunized with the complete vaccine formulations or immunized 335 
with adjuvants only. 336 
 337 
The effects of re-exposure to infection after clearance of an infection and 338 
immunization were examined. Upon secondary genital infection with C. muridarum 339 
all animals in all groups became re-infected at very low levels, in comparison to the 340 
level of infection seen on primary exposure, including the animals receiving live 341 
immunizations (LIC; Fig. 6C). Interestingly, even though all animals had previously 342 
been exposed to a genital infection and immunized with our vaccine candidates, they 343 
still became infected upon secondary infection. However, the level of C. muridarum 344 
recovered from the lower genital tracts of animals receiving the secondary infection 345 
did not reach the challenge dose of 5 x 104 ifu and the course of infection was also 346 
reduced from 28 days to 9 days. 347 
 348 
 
 
The timing of vaccination has no effect on the development of hydrosalpinx 349 
The degree of hydrosalpinx formation in mice was measured. This revealed that 350 
there were no significant differences in the scores between any of the groups at any 351 
of the time-points examined (Fig. 7). There was, however, a trend showing less 352 
severe hydrosalpinx development in those mice immunized with the complete 353 
vaccine formulations after clearance of infection. This highlighted that the timing of 354 
vaccination did not enhance gross pathology development. 355 
 356 
The timing of vaccination does not affect inflammatory cell infiltration into the 357 
upper reproductive tract 358 
The inflammatory cell infiltrate into the uterine horns of animals was examined via 359 
H&E staining. There was a trend with animals immunized intranasally with the 360 
complete vaccine formulations after infection having greater neutrophil influx than 361 
control mice (Fig. 8A); however this was not above that of the infection control, 362 
suggesting the immunizations did not cause this infiltration. There were no significant 363 
differences observed in lymphocyte infiltration (Fig. 8B) between any of the groups 364 
immunized at the various stages of infection. Assessment of the reproductive tissues 365 
of those immunized after an infection and those re-exposed to an infection, revealed 366 
a slightly higher, but not significant, infiltration of plasma cells, than that seen in the 367 
infection control animals (Fig. 8C). Importantly, comparison of those animals 368 
immunized either during or after infection to those immunized before infection 369 
demonstrates that the timing of vaccination does not influence the inflammatory cell 370 
infiltration into the upper reproductive tract. 371 
 372 
 373 
 
 
The inflammatory cell infiltrate into the oviducts of mice was examined, and it was 374 
found that there was no cellular infiltrate present (data not shown). However, due to 375 
the development of hydrosalpinx, the oviducts had lost their natural structure, 376 
including the loss of the ciliated epithelium. The oviduct of an uninfected mouse had 377 
normal plicae with a ciliated epithelium and secretory cells present. In comparison, 378 
those mice that were infected with C. muridarum had developed hydrosalpinx, which 379 
caused the destruction of ciliated epithelium and a total loss of structure within the 380 
oviduct, including loss of plicae and a flattened or denuded epithelium that is 381 
consistent with pressure atrophy. 382 
 383 
 384 
 385 
 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 
 
Discussion 399 
 400 
The number of C. trachomatis infections of the female reproductive tract has been 401 
steadily increasing over the last 10 years [23], and this current number could quite 402 
possibly be higher, due to the asymptomatic nature of infections. This highlights the 403 
need for the development of an efficacious vaccine that protects not only against 404 
infection, but also prevents the development of any pathological sequelae. Even with 405 
the considerable amount of research into the development of a Chlamydia vaccine, 406 
there has been no examination of the effects of the timing of vaccination, with regard 407 
to immunization after previous exposure or during an acute infection.  408 
 409 
We have, for the first time, examined the effects of administration of a single and 410 
multi-subunit vaccine candidate on the subsequent immune responses of animals 411 
acutely or previously infected with C. muridarum. This study also investigated, for the 412 
first time, any effects the timing of immunization had on the development of infection-413 
associated pathology, including hydrosalpinx formation and inflammatory cell 414 
infiltration into the upper genital tract. It was found that while the timing of vaccination 415 
affected the systemic production of antibodies, it had a minimal effect on the 416 
secretion of mucosal antibodies in the vagina and uterus of the mice. Of importance, 417 
it was found that the timing of immunizations did not significantly enhance the 418 
development of gross pathology or inflammatory cell infiltrate into the upper 419 
reproductive tracts of vaccinated mice. This is the first time that any chlamydial 420 
vaccine candidate has been used to examine the effects of immunization on those 421 
animals with a genital tract infection or those previously exposed to such an 422 
infection. 423 
 
 
 424 
We observed that immunization during an acute infection or after clearance of one, 425 
boosted systemic MOMP-specific IgG antibody production, and to lesser extent 426 
NrdB-specific antibodies, however, this did not occur at the mucosal surfaces. The 427 
vaccine candidates used in this study have previously been shown to induce strong 428 
mucosal antibody responses [19, 20, Cunningham, unpublished data], however in 429 
our current study, vaginal and uterine lavage IgA antibodies detected were not above 430 
those of the infection time point controls, indicating that immunization did not 431 
enhance their secretion. NrdB is expressed by the reticulate bodies of Chlamydia 432 
during the intracellular stage of infection; therefore antibodies against NrdB would be 433 
expected to be found in animals that have had an infection. However, in this study 434 
animals that had been infected either once or twice did not produce systemic NrdB-435 
specific IgG, the reason for this is unknown. A similar situation has been observed in 436 
varicella zoster virus (VZV) vaccine trials in seropositive adults, where vaccination 437 
was via inhalation [24]. Those individuals given live attenuated or heat killed 438 
vaccines had a > 2 fold increase in systemic antibodies, but had no significant 439 
increase in secretory IgA in the saliva [24]. Also, in Herpes simplex virus – 2 (HSV-2) 440 
vaccine trials, individuals who were seropositive for HSV-1 but seronegative for 441 
HSV-2, and those who were seronegative for both, were immunized against HSV-2 442 
infection. It was found that the vaccine was only effective in those seronegative to 443 
both HSV-1 and 2 [25]. This is suggested to occur because immunity to the virus has 444 
been previously provided by infection with a different strain and administration of a 445 
vaccine does not enhance any response [25], and may also be the case seen in the 446 
results presented in this study. 447 
 448 
 
 
In terms of the T cell production of cytokines, quite the opposite was seen, with 449 
increases in IL-10 and IFN-γ in those mice immunized during or after clearance of 450 
infection in comparison to those immunized naive. These increases are likely due to 451 
the fact that a longer time post infection has elapsed enabling the vaccination to 452 
boost the developed T cell memory response. 453 
 454 
The inability of animals in our study to mount an enhanced immune response after 455 
vaccination, when either actively, or previously infected with C. muridarum, may be 456 
partly due to dendritic cell (DC) function. When animals become infected, immature 457 
DCs phagocytose chlamydial particles, process them, and present the chlamydial 458 
antigens through MHC molecules, thereby becoming mature DCs [26]. During the 459 
maturation process, upon exposure to Chlamydia, DCs also up-regulate their 460 
expression of surface receptors, including CD80, CD40 and CD86 [27]. However, it 461 
has recently been shown that DCs, isolated from BALB/c mice, infected with C. 462 
muridarum down-regulate both CD80 and CD86 surface receptors [28], which is able 463 
to subvert the normal function of these cells from normally inducing a Th1 response, 464 
to causing a Th2 response [28]. More importantly, once DCs become mature, they 465 
have been found to down-regulate MHC II synthesis, which prevents the formation of 466 
new MHC II peptide complexes in mature DCs [29]. Both a down-regulation of 467 
surface receptors due to infection and a down-regulation of MHC II complexes may 468 
contribute to the lack of enhanced immune response in the animals immunized either 469 
during or after infection in this study. This is likely due to the inability of DCs to 470 
process and present new/more antigens to B cells, thereby not enhancing the 471 
number of antigen specific B cells, and therefore restricting the levels of antibody 472 
production. Chlamydia infection is also able to inhibit IFN-γ-inducible MHC II 473 
 
 
expression [30], possibly further reducing the host’s ability to mount an effective 474 
immune response.  475 
 476 
In this study, it was found that the complete vaccine compositions had no therapeutic 477 
effect. This was not surprising, as there are currently no therapeutic vaccines that 478 
target the female reproductive tract approved for human use. However, there are 479 
some in development, including those against human immunodeficiency virus (HIV) 480 
and human papillomavirus (HPV). HPV studies in rabbits, using the cottontail rabbit 481 
papillomavirus, and a HPV L1 virus-like particle (VLP) vaccine, have demonstrated 482 
regression of established papillomas [31], and other studies using various delivery 483 
systems and HPV antigens have shown a reduction in disease or regression of warts 484 
[32]. Clinical trials of the human approved HPV vaccine, Gardasil, revealed that it 485 
had no therapeutic effect on those who were already seropositive for HPV [33]. 486 
Since HIV was identified as the aetiologic agent for AIDS, there have been more 487 
than 40 therapeutic vaccine candidates that have progressed to human clinical 488 
testing, with little success [34]. The use of MOMP or MOMP and NrdB in 489 
combination, administered intranasally, after clearance of a genital infection did not 490 
provide protection above that induced by the infection alone. These antigens have 491 
previously proved to provide partial protection against a genital infection in mice 492 
immunized naive [18, 20]. However, this study highlights that a vaccine with antigens 493 
that induce greater protective immunity and perhaps different adjuvants, would be 494 
required to provide total protection against re-infection. At this point in time a vaccine 495 
that provides total protection against a genital tract chlamydial infection does not 496 
exist.  497 
 498 
 
 
In this study the effects of the timing of vaccination on the development of upper 499 
reproductive tract pathology in mice was also examined. We have demonstrated that 500 
neither immunization during an active genital tract chlamydial infection, nor after 501 
clearance of a primary chlamydial genital infection, significantly enhanced 502 
hydrosalpinx development or inflammatory cell infiltration. However, while it did not 503 
enhance pathology, it also did not protect animals from further pathology upon re-504 
infection of the genital tract. Those animals that were re-challenged with C. 505 
muridarum after having received an immunization after clearance of a primary 506 
infection still developed hydrosalpinx. Interestingly, we also observed that those 507 
animals that were immunized after infection had lower levels of hydrosalpinx 508 
development than the other groups examined. Hydrosalpinx occurs when the 509 
oviducts have become occluded from scar tissue development or cellular debris 510 
accumulation, causing clear, serous fluid to accumulate and dilate the oviduct [35]. It 511 
is also used as a marker of infertility in the mouse model [35, 36]. It has been 512 
suggested, that over time, hydrosalpinx is able to resolve in immunocompetent mice 513 
[37], which might have occurred here due to the extended time period of the 514 
experiment. Hydrosalpinx fluid has also been suggested to leak into the uterine 515 
cavity [38, 39], and may also explain some of the decrease in severity seen here. 516 
 517 
Importantly, immunization with these particular sub-unit vaccines during an infection, 518 
or after clearance of a genital infection did not enhance inflammatory cell infiltration 519 
into the upper reproductive tract. It is highly possible, depending on the particular 520 
vaccine candidate and the type of immune response mounted, that an immunization 521 
during, or after an infection, could enhance pathology development [40]. Both 522 
antigens used here, administered intranasally with CT and CpG, have previously 523 
 
 
been shown to cause the production of cytokines, including IFN-γ, TNF-α and IL-10 524 
[18, 20, Cunningham, unpublished data]. The production of IFN- by CD4+ T cells 525 
has proved to be essential in the clearance of Chlamydia from the genital tract. 526 
However, secretion of other pro-inflammatory cytokines, including TNF-, has been 527 
suggested to be involved in triggering inflammation [17] and infection related 528 
pathologies such as salpingitis [41]. The induction of these other pro-inflammatory 529 
cytokines may increase the risk of further upper reproductive tract pathology 530 
enhancement. Previous trachoma vaccine trials used whole killed Chlamydia to 531 
immunize previously infected blind individuals [14]. It was found that those that had 532 
been previously exposed to infection developed a greater degree of pathology upon 533 
re-exposure, compared to those individuals who had not been previously infected 534 
[14]. Similar studies were performed in monkeys and similar results were obtained 535 
[15, 16]. This was thought to be linked to the presence of chlamydial HSP-60 and 536 
cross-reactivity with self HSP-60 and suggests that if chlamydial HSP-60 was to be 537 
used as an antigen this would enhance pathological sequelae development in the 538 
reproductive tract. This highlights the importance of examination of antigens under 539 
the conditions presented here. 540 
 541 
Overall, we have demonstrated for the first time that the timing of vaccination does 542 
not enhance the development of infection-associated reproductive tract pathology, 543 
and have shown that these same vaccinations do not boost the local infection-544 
induced antibody response in the female genital tract of mice. This does not mean 545 
that other sub-unit vaccines will not induce a greater memory response and cause 546 
pathological sequelae, but highlights the importance of trialing vaccines under 547 
various host infection states. Based on the studies presented here, if similar results 548 
 
 
were obtained from human clinical trials, it would not be cost effective to vaccinate 549 
individuals who were seropositive for a current or previous C. trachomatis infection, 550 
as it would not provide enhanced protection. This is the first time that a sub-unit 551 
vaccine candidate has been used to examine the effects of immunization during an 552 
active, possibly asymptomatic genital infection, or after clearance of a previous 553 
genital infection. These are important factors that need to be examined during 554 
vaccine design due to the asymptomatic nature of infection and the increasing rate of 555 
infections.  556 
 557 
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